22
Views
30
CrossRef citations to date
0
Altmetric
Articles

Prognostic Factors in Patients with Localized Ewing’s Sarcoma: The effect on survival of actual received drug dose intensity and of histologic response to induction therapy

Pages 352-363 | Published online: 18 Jul 2013

References

  • Sneath RS, Carter SR, Grimer RJ. Ewing's sarcoma. Fifteen years of experience. Chir Organi Mov 1990; 80 suppl 1: 260-61.
  • Barbieri E, Emiliano Zini G, Mancini A, et al. Combined therapy of localised Ewing's sarcoma of bone. Analysis of results in 100 patients. Int J Radiat Oncol Biol Phys 1990; 19: 1165–70.
  • Jiirgens H, Exner U, Gadner H, et al. Multidisciplinary treatment of primary Ewing's sarcoma of bone. A 6 year experience of an European cooperative trial. Cancer 1988; 61, 23–32.
  • Evans RG, Nesbit ME, Gehan EA, et al. Multimodal therapy for the management of localised Ewing's sarcoma of pelvic and sacral bones. A report from the second intergroup study. J Chin Oncol 1991: 7: 1173–80.
  • Nesbit ME, Perez CA, Teeft M, et al. Multimodal thera-py for the management of primary non metastatic Ewing's sarcoma of bone: an intergroup study. Natl Cancer Inst Monogr 1981; 56: 255–62.
  • Klaassen R, Sastregarau X, Aurias A, et al. Sarcome d'Ewing osseux de l'adulte. Etude anatomoclinique de 30 observations. Bull Cancer 1992; 79: 161–7.
  • Bacci G, Picci P, Gitelis S, Borghi A, Campanacci M. The treatment of localised Ewing's sarcoma: the experience at the Istituto Ortopedico Rizzoli in 163 cases treated with and without adjuvant chemotherapy. Cancer 1982; 49: 1561-70.
  • Glaubiger DL, Makuch R, Schwarz J, Levine AS, Johnson RE. Determination of prognostic factors and their influence on therapeutic results in patients with Ewing's sar-coma. Cancer 1980; 45: 2213–9.
  • Marcus RB, Million RR. The effect of primary tumor size on the prognosis of Ewing's sarcoma. Int J Radiat Oncol Biol Phys 1984; 10 (suppl): 2-8.
  • Hayes FA, Thompson El, Meyer WA, et al. Therapy for localised Ewing's sarcoma of bone. J Chin Oncol 1989; 7: 208–13.
  • Cangir C, Vietti TJ, Gehan EA, et al. Ewing's sarcoma metastatic at diagnosis. Results and comparisons of two inter-group Ewing's sarcoma studies. Cancer 1990; 66: 887–93.
  • Vietti TJ, Gehan EA, Nesbit ME Jr, et al. Multimodal therapy in metastatic Ewing's sarcoma: an intergroup study. Natl Cancer Inst Monogr 1981; 56: 279–84.
  • Sinkovics JG, Plager C, Ayola AG, Lindberg RD, Samuela ML. Ewing's sarcoma. Its course and treatment in 50 adults patients. Oncology 1980; 37: 114–9.
  • Bullimore JA. Ewing's sarcoma in adults. Chin Oncol 1990; 2, (1): 39–45.
  • Oberlin O, Habrand JL, Ziicker JM, et al. No benefit of IFX in Ewing's sarcoma: a non randomised study of the French Society of Pediatric Oncology. J Chin Oncol 1992; 10: 1407-12.
  • Oberlin O, Zucker JM, Brunat-Mentigny M, et al. Prognostic factors in localised Ewing's sarcoma. A study of the French Society of Pediatric Oncology. Med Ped Oncol 1993; 21, 8: 573 (abstract 74, XXV SIOP meeting).
  • Picci P, Rougraff BT, Bacci G, et al. Prognostic significance of histopathologic response to chemotherapy in non metastatic Ewing's sarcoma of the extremities. J Clin Oncol 1993; 11: 1763–69.
  • Enneking WF, Spanier SS, Goodman MA: A system for the surgical staging of musculoskeletal sarcoma. Clin Ortho 1980; 153: 106–10.
  • Lewis RJ, Marcove RC, Rosen G. Ewing & Sarcoma - functional effects of radiation therapy. J Bone Joint Surg 1977; 59A: 325–32.
  • Arlen M, Higinbotham NL, Huvos AG, Marcove RC, Miller T, Shatt IC. Radiation induced sarcoma of bone. Cancer 1971; 28: 1087–99.
  • Li FP. Second malignant tumors after cancer in child-hood. Cancer 1977; 40: 1899–902.
  • Strong LC, Hersen J, Osborne BM, Salow WN. Risk of radiation related subsequent malignant tumor in survivors of Ewing's sarcoma. J Natl Cancer Inst, 1979; 62: 1401–06.
  • Markowska B, Delepine N, Delepine G, et al. Low car-diotoxicity of pirarubicin in solid tumors in children; an analysis of 71 cases. (abstract) J Clin Oncol 1994; 13: 413.
  • Siegel RD, Ryan LM, Antman KH. Adults with Ewing's sarcoma. An analysis of 16 patients at the Dana Farber Cancer Institute. Am J Clin Oncol 1988; 11, 6: 614-7.
  • Meyer RM, Hryniuk WM, Goodyear MDE. The role of dose intensity in determining outcome of intermediate-grade-non-Hodgkin's lymphoma. J Clin Oncol 1991; 9: 339–47.
  • Nesbit ME, Gehan EA, Burgert EO, et al. Multimodal therapy for the management of primary non metastatic Ewing's sarcoma of bone. A long term follow up of the first intergroup study. J Clin Oncol 1990; 8, 10: 1664–74.
  • Evans R, Nesbit M, Askin F, et al. Local recurrence, rate and sites of metastases, and time to relapse as a function of treatment regimen, size of the primary and surgical history in 62 patients presenting with non metastatic Ewing's sarco-ma of the pelvic bones. Int J Rad Oncol Biol Physiol 1985; 11: 129–36.
  • Burgert EO, Nesbit ME, Garnsey LA, et al. Multimodal therapy for the management of non pelvic localised Ewing's sarcoma of bone. Intergroup study IESS II. J Oncol 1990; 8: 1514–24.
  • Smith MA, Ungerleider RS, Horowitz ME. Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma. J Natl Cancer Inst 1991; 83, 20: 1460–70.
  • Haim N, Epelbaum R, Ben-shahar M, Yarnitsky D, Simri W, Robinson E. Full dose vincristine (without 2-mg dose limit) in the treatment of lymphomas. Cancer 1994; 73: 2515–9.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.